ArticleTranslational gastroenterology and hepatology2026
Integrated bioinformatics analysis of prognostic significance and molecular regulation of mitochondrial metabolism-related genes in colorectal cancer.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The development and progression of colorectal cancer (CRC) are closely associated with metabolic reprogramming, in which mitochondrial metabolism is critically associated with tumor cell survival and proliferation. This study aims to provide novel insights for mitochondrial metabolism-related genes (MMRGs)-based prognosis prediction, biomarker discovery, and the development of targeted therapeutic strategies in CRC. Methods: Based on multi-omics data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) (including single-cell RNA-seq), we systematically analyzed MMRGs through differential expression screening, functional enrichment, least absolute shrinkage and selection operator (LASSO) regression modeling, and independent validation, supplemented by cell-cell communication, immune infiltration, drug sensitivity, and regulatory network analyses. Results: We identified 7 major cell types and uncovered the immune microenvironment characteristics in CRC patients. We constructed a novel MMRGs-centric prognostic signature (CD36/ACOX1) validated in TCGA and GEO cohorts, effectively stratifying patients into distinct risk groups with significant survival differences. The risk model demonstrated independent prognostic value, correlated with distinct immune landscapes and genomic features. Regulatory network analysis revealed miRNA/TF interactions targeting CD36/ACOX1, while drug sensitivity screening identified 81 therapeutic agents with enhanced efficacy in high-risk patients. Pseudotime trajectory analysis further uncovered novel B-cell differentiation dynamics associated with prognostic gene expression. Conclusions: The mitochondrial metabolic signature CD36/ACOX1 enables robust survival stratification in CRC. This clinically applicable model informs tumor microenvironment dynamics and precision oncology frameworks for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.